The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Open accessAbstract
BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide-azathioprine), are unknown. METHODS: , and no use of rescue therapy). The time to a renal-related event or death was assessed. RESULTS: A total of 448 patients underwent randomization (224 to the belimumab group and 224 to the placebo group). At week 104, significantly more patients in the belimumab group than in the placebo group had a primary efficacy renal response (43% vs. 32%; odds ratio, 1.6; 95% confidence interval [CI], 1.0 to 2.3; P = 0.03) and a complete renal response (30% vs. 20%; odds ratio, 1.7; 95% CI, 1.1 to 2.7; P = 0.02). The risk of a renal-related event or death was lower among patients who received belimumab than among those who received placebo (hazard ratio, 0.51; 95% CI, 0.34 to 0.77; P = 0.001). The safety profile of belimumab was consistent with that in previous trials. CONCLUSIONS: In this trial involving patients with active lupus nephritis, more patients who received belimumab plus standard therapy had a primary efficacy renal response than those who received standard therapy alone. (Funded by GlaxoSmithKline; BLISS-LN ClinicalTrials.gov number, NCT01639339.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group (2010) · BMJ · doi:10.1136/bmj.c332 · Cited by 9,329
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
Research works printed but not linked: 38
- 10.1038/s41590-019-0398-x · DOI · Paper page
- 10.1038/s41572-019-0141-9 · DOI · Paper page
- 10.1038/s41584-020-0401-9 · DOI
- 10.2174/1574887112666171123113200 · doi:10.2174/1574887112666171123113200
- 10.1093/rheumatology/kev311 · DOI · Paper page
- 10.1093/ndt/gfs073 · DOI · Paper page
- 10.1002/art.39594 · DOI · Paper page
- 10.1016/S0140-6736(10)61354-2 · DOI · Paper page
- 10.1002/art.30613 · DOI · Paper page
- 10.1177/0961203312465781 · DOI · Paper page
- 10.1002/art.10461 · DOI · Paper page
- 10.1136/ard.2010.131995 · DOI · Paper page
- 10.1681/ASN.2008101028 · DOI · Paper page
- 10.1056/NEJMoa1014460 · DOI · Paper page
- 10.3899/jrheum.161554 · DOI
- 10.1002/art.39026 · DOI · Paper page
- 10.1136/annrheumdis-2014-206897 · DOI · Paper page
- Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev 2018;6:CD002922-CD002922.29957821
- 10.1038/nrneph.2012.220 · DOI
- 10.1155/2013/954292 · doi:10.1155/2013/954292
- 10.4049/jimmunol.1600281 · DOI
- 10.1177/0961203317717083 · doi:10.1177/0961203317717083
- 10.1177/0961203317739132 · DOI
- 10.1007/s10238-019-00549-8 · DOI
- 10.1002/art.34400 · DOI · Paper page
- 10.1136/lupus-2017-000213 · doi:10.1136/lupus-2017-000213
- 10.1002/art.34624 · DOI
- 10.1186/s13075-015-0621-6 · doi:10.1186/s13075-015-0621-6
- 10.1136/annrheumdis-2020-eular.2983 · doi:10.1136/annrheumdis-2020-eular.2983
- 10.1136/annrheumdis-2012-201940 · DOI · Paper page
- 10.1002/acr.21664 · DOI · Paper page
- 10.1038/ki.1994.70 · DOI · Paper page
- 10.1002/acr.20397 · DOI
- 10.3899/jrheum.130005 · DOI
- 10.1038/sj.ki.5000243 · DOI · Paper page
- 10.1681/ASN.2006090992 · doi:10.1681/asn.2006090992
- 10.1002/art.34359 · DOI · Paper page
- 10.1002/art.38260 · DOI · Paper page
Cited by
Furie, R. A., Aroca, G., Cascino, M. D., Garg, J. P., Rovin, B. H., Alvarez, A., Fragoso-Loyo, H., Zuta-Santillan, E., Schindler, T., Brunetta, P., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220920 · Cited by 459
Self-citationHoi, A., Igel, T., Mok, C. C., & Arnaud, L. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00398-2 · Cited by 399
Self-citationImmunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Belimumab, an antiB-cell-activating factor (BAFF), is another B-cell-depleting antibody that has shown promising results in controlling autoimmune diseases [171, 172].”
BackgroundThe Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?
Piga, M., & Arnaud, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020243 · Cited by 99
Metadata
- Authors
- Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., Saxena, A., Green, Y., Ji, B., Kleoudis, C., Burriss, S. W., Barnett, C., & Roth, D. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-09-17
- Volume
- 383
- Issue
- 12
- Pages
- 1117-1128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3085025551
- Cited by
- 1,032
- References
- 2
- FWCI
- 81.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- GSK (GSK Study 114054)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. https://app.cochat.ai/papers/10.1056/nejmoa2001180
- The paper
- Furie, R., Rovin, B. H., Houssiau, F., Malvar, A., Teng, Y. K. O., Contreras, G., Amoura, Z., Yu, X., Mok, C.-C., Santiago, M. B., Saxena, A., Green, Y., Ji, B., Kleoudis, C., Burriss, S. W., Barnett, C., & Roth, D. A. (2020). Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2001180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
